Foxchart.com
Reata Pharmaceuticals, Inc. (RETA)
172.36  0.04 (0.02%)  09-25 16:00
Open: 172.34
High: 172.46
Low: 172.32
Volume: 1,909,215
Market Cap: 6,566(M)
PE Ratio: -66.29
Exchange: NASDAQ Global Market
Industry: Biotechnology
Sector: Healthcare
Technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell buy
Resistance 2: 201.43
Resistance 1: 172.46
Pivot price: 171.64
Support 1: 170.05
Support 2: 168.56
52w High: 172.46
52w Low: 21.83
Watchlist
MSFT0 (0%)
TWTR0 (0%)
BAC0 (0%)
AMZN0 (0%)
FB0 (0%)
GM0 (0%)
Zoom in Zoom out
Draw lines
Horizontal lines
Parallel lines
Fibonacci lines
Remove studies
Shot and share

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Financials
EPS -167630000.000
Book Value -2.600
PEG Ratio 0.00
Gross Profit -54.653
Profit Margin (%) 0.00
Operating Margin (%) -1.00
Return on Assets (ttm) 455.1
Return on Equity (ttm) -37.7
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
×
Share on Facebook Tweet this page

Foxchart international:  |  United States  |  Canada  |  United Kingdom  |  Australia  |  New Zealand  |  Singapore  |  India

©Foxchart.com All Rights Reserved. Foxchart.com | United States NYSE NASDAQ AMEX stock markets, stock quotes and stock technical analysis charts. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither Foxchart.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX